Antiviral Therapies for Adults with Mild to Moderate COVID-19 Infection

With increasing population immunity through vaccination and prior infection, the risk of severe COVID-19, hospitalization, and death has substantially decreased in all age groups in the US since 2021.1 However, certain populations, especially those aged 65 years or older, remain at increased risk for progression to severe disease. This updated guideline provides a risk-stratified approach to antiviral therapies for patients with mild to moderate COVID-19 (defined as symptoms of respiratory infection with oxygen saturation >94% while breathing room air). Antiviral therapies are most effective when initiated within 5 to 7 days of COVID-19 symptom onset.